The objective of this study is to determine the ability of metformin treatment in reducing the prevalence of metabolic syndrome (MS) and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome (PCOS).
Gangale, M., Miele, L., Lanzone, A., Sagnella, F., Martinez, D., Tropea, A., Moro, F., Morciano, A., Ciardulli, A., Palla, C., Pompili, M., Cefalo, C., Apa, R., Grieco, A., Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome, <<CLINICAL ENDOCRINOLOGY>>, 2011; 75 (4): 520-527. [doi:10.1111/j.1365-2265.2011.04093.x] [http://hdl.handle.net/10807/16366]
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome
Miele, Luca;Lanzone, Antonio;Sagnella, Francesca;Martinez, Daniela;Moro, Francesca;Morciano, Andrea;Pompili, Maurizio;Cefalo, Consuelo;Apa, Rosanna;
2011
Abstract
The objective of this study is to determine the ability of metformin treatment in reducing the prevalence of metabolic syndrome (MS) and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome (PCOS).
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
